In vivo biodistribution of no-carrier-added 6-18F-fluoro-3, 4-dihydroxy-L-phenylalanine (18F-DOPA), produced by a new nucleophilic substitution approach, compared with carrier-added 18F-DOPA, prepared by conventional electrophilic substitution

Journal of Nuclear Medicine

Volumn 56, Issue 1, 2015, Pages 106-112

  Kuik, Willem Jan ^a   Kema, Ido P ^a   Brouwers, Adrienne H ^a   Zijlma, Rolf ^a   Neumann, Kiel D ^b   Dierckx, Rudi A J O ^a   DiMagno, Stephen G ^c   Elsinga, Philip H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Ground Fluor Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

18F; 18F DOPA; Diaryliodonium salt; Neuroendocrine tumors; PET

Indexed keywords

6 FLUORODOPA F 18; CARBIDOPA; TETRABENAZINE; DOPA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG STABILITY; DRUG STRUCTURE; DRUG UPTAKE; IMAGE ANALYSIS; IMAGE QUALITY; IN VIVO STUDY; LOW TEMPERATURE; MALE; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREATIC NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DIAGNOSTIC USE; HUMAN; PROCEDURES; RADIOCHEMISTRY; SCINTISCANNING; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DIHYDROXYPHENYLALANINE; DRUG STABILITY; HUMANS; MALE; MICE; NEUROENDOCRINE TUMORS; POSITRON-EMISSION TOMOGRAPHY; RADIOCHEMISTRY; TISSUE DISTRIBUTION;

EID: 84920380789     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.114.145730     Document Type: Article

References (31)

1. 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. Eur J Nucl Med Mol Imaging. 2013; 40: 943-966.
2. 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol. 2006; 7: 728-734.
3. 11C-5- hydroxy-tryptophan positron emission tomography. J Clin Oncol. 2008; 26: 1489-1495.
4. 18F-FDOPA PET. J Nucl Med. 2013; 54: 42-49.
5. Seibyl JP, Chen W, Silverman DH. 3, 4-dihydroxy-6-18fluoro-L-phenylalanine positron emission tomography in patients with central motor disorders and in evaluation of brain and other tumors. Semin Nucl Med. 2007; 37: 440-450.
6. Sioka C, Fotopoulos A, Kyritsis AP. Recent advances in PET imaging for evaluation of Parkinson's disease. Eur J Nucl Med Mol Imaging. 2010; 37: 1594-1603.
7. 18F]fluoro-L-dopa. Int J Rad Appl Instrum [A]. 1992; 43: 989-996.
8. 18F] fluoro-l-DOPA. Appl Radiat Isot. 1999; 51: 389-394.
9. 18F]fluoronorepinephrine via the nucleophilic aromatic substitution reaction. J Med Chem. 1991; 34: 767-771.
10. 18F]fluorodopa via NCA nucleophilic fluorination. Int J Rad Appl Instrum [A]. 1991; 42: 629-635.
11. 18F]fluoro-L-dopa by chiral phasetransfer alkylation. Eur J Org Chem. 2004; 2004: 2899-2904.
12. 18F-fluoro-L-dopa. J Nucl Med. 2013; 54: 1154-1161.
13. Wagner FM, Ermert J, Coenen HH. Three-step, "one-pot" radiosynthesis of 6-fluoro-3, 4-dihydroxy-L-phenylalanine by isotopic exchange. J Nucl Med. 2009; 50: 1724-1729.
14. DiMagno SG, inventor; Nutech Ventures, assignee. Fluorination of aromatic ring systems. US Patent 8, 604, 213 B2. December 10, 2013.
15. Yanagida O, Kanai Y, Chairoungdua A, et al. Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta. 2001; 1514: 291-302.
16. Kaira K, Oriuchi N, Imai H, et al. Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung. Pathol Res Pract. 2008; 204: 553-561.
17. Kaira K, Oriuchi N, Imai H, et al. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer. 2008; 98: 742-748.
18. Furuya M, Horiguchi J, Nakajima H, Kanai Y, Oyama T. Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. Cancer Sci. 2012; 103: 382-389.
19. Kaira K, Oriuchi N, Imai H, et al. l-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms. Cancer Sci. 2008; 99: 2380-2386.
20. Isobe K, Nakai T, Yukimasa N, Nanmoku T, Takekoshi K, Nomura F. Expression of mRNA coding for four catecholamine-synthesizing enzymes in human adrenal pheochromocytomas. Eur J Endocrinol. 1998; 138: 383-387.
21. Vachtenheim J, Novotna H. Expression of the aromatic L-amino acid decarboxylase mRNA in human tumour cell lines of neuroendocrine and neuroectodermal origin. Eur J Cancer. 1997; 33: 2411-2417.
22. Eissele R, Anlauf M, Schafer MK, Eiden LE, Arnold R, Weihe E. Expression of vesicular monoamine transporters in endocrine hyperplasia and endocrine tumors of the oxyntic stomach. Digestion. 1999; 60: 428-439.
23. Voland P, Besig S, Rad R, et al. Correlation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinase expression in ileal carcinoids, lymph nodes and liver metastasis with prognosis and survival. Neuroendocrinology. 2009; 89: 66-78.
24. Brunk I, Blex C, Rachakonda S, et al. The first luminal domain of vesicular monoamine transporters mediates G-protein-dependent regulation of transmitter uptake. J Biol Chem. 2006; 281: 33373-33385.
25. Peehl DM, Coram M, Khine H, Reese S, Nolley R, Zhao H. The significance of monoamine oxidase-A expression in high grade prostate cancer. J Urol. 2008; 180: 2206-2211.
26. Grouzmann E, Matter M, Bilz S, et al. Monoamine oxidase A down-regulation contributes to high metanephrine concentration in pheochromocytoma. J Clin Endocrinol Metab. 2012; 97: 2773-2781.
27. 11C-harmine. Nucl Med Biol. 2003; 30: 669-679.
28. 18F-fluorodihydroxyphenylalanine in a patient with metastatic carcinoid. J Nucl Med. 2005; 46: 1240-1243.
29. Ohtsuki S, Yamaguchi H, Kang YS, Hori S, Terasaki T. Reduction of L-type amino acid transporter 1 mRNA expression in brain capillaries in a mouse model of Parkinson's disease. Biol Pharm Bull. 2010; 33: 1250-1252.
30. Miller GW, Erickson JD, Perez JT, et al. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp Neurol. 1999; 156: 138-148.
31. Harrington KA, Augood SJ, Kingsbury AE, Foster OJ, Emson PC. Dopamine transporter (dat) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson's disease. Brain Res Mol Brain Res. 1996; 36: 157-162.